Pacira BioSciences Inc. (PCRX)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 0 |
| Ownership rank: | -- |
| % of all portfolios: | 0% |
| History | Portfolio Manager | Activity ▼ | Share change | % change to portfolio | |
| Q2 2023 | |||||
| ≡ | First Eagle Investment Management | Add 38.46% | 67,847 | 0.01 | |
| ≡ | Lee Ainslie - Maverick Capital | Buy | 5,823 | 0.00 | |
| Q1 2023 | |||||
| ≡ | First Eagle Investment Management | Add 112.53% | 93,412 | 0.01 | |
| Q4 2022 | |||||
| ≡ | First Eagle Investment Management | Add 5.71% | 4,482 | 0.00 | |
| Q3 2022 | |||||
| ≡ | First Eagle Investment Management | Add 12.47% | 8,706 | 0.00 | |
| Q2 2022 | |||||
| ≡ | First Eagle Investment Management | Add 46.32% | 22,104 | 0.00 | |
| Q1 2022 | |||||
| ≡ | First Eagle Investment Management | Add 92.18% | 22,889 | 0.00 | |
| Q4 2021 | |||||
| ≡ | First Eagle Investment Management | Buy | 24,832 | 0.00 | |
| Q2 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 1,108 | 0.00 | |
| Q3 2019 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 172,380 | 0.10 | |
| Q1 2016 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 1,610,932 | 1.35 | |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.